European urology · 2025
Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meghani Khyati, Yu Yanni, Frydenlund Noah, Li Erik Z, Choy Bonnie, Abdulkadir Sarki A, Meeks Joshua J
Аннотация
BACKGROUND AND OBJECTIVE: High-risk bladder cancer recurs in 30% of cases and causes fatal outcomes in 10% within 2 yr despite surgical resection, endoscopic surveillance, and bacillus Calmette-Guérin (BCG) immunotherapy. The global shortage of BCG highlights the urgent need for alternative or complementary strategies. This study aimed to identify molecular subtypes and develop a precision framework to predict recurrence risk and guide treatment.
METHODS: Transcriptomic profiling and targeted genomic sequencing were performed with validation by single-cell RNA sequencing and spatial transcriptomics. A machine learning model incorporating genomic and transcriptomic features was developed to predict recurrence risk.
KEY FINDINGS AND LIMITATIONS: Four subtypes were identified, and an inflamed tumor subtype with high endogenous retroelement expression and increased commensal bacterial presence demonstrated the highest responsiveness to BCG therapy. The predictive model achieved high accuracy (area under the curve = 0.87, 95% confidence interval: 0.72-1.0) for recurrence risk. Findings are limited by sample size, necessitating validation in larger cohorts.
CONCLUSIONS AND CLINICAL IMPLICATIONS: We describe a new conceptual framework for T1 tumors. Those with increased immune cells (subtype 2) have a better response to BCG, which may be secondary to enhanced baseline immune activity.
METHODS: Transcriptomic profiling and targeted genomic sequencing were performed with validation by single-cell RNA sequencing and spatial transcriptomics. A machine learning model incorporating genomic and transcriptomic features was developed to predict recurrence risk.
KEY FINDINGS AND LIMITATIONS: Four subtypes were identified, and an inflamed tumor subtype with high endogenous retroelement expression and increased commensal bacterial presence demonstrated the highest responsiveness to BCG therapy. The predictive model achieved high accuracy (area under the curve = 0.87, 95% confidence interval: 0.72-1.0) for recurrence risk. Findings are limited by sample size, necessitating validation in larger cohorts.
CONCLUSIONS AND CLINICAL IMPLICATIONS: We describe a new conceptual framework for T1 tumors. Those with increased immune cells (subtype 2) have a better response to BCG, which may be secondary to enhanced baseline immune activity.